HYPE: Urolithin A renews mitochondria, improves muscle and slows ageing.
But what does the evidence actually show?
Defined preparations have human trials with selected endurance and biomarker signals. Evidence for broader muscle function remains uncertain, and slower biological ageing or longer life has not been demonstrated.
Why the mechanism is interesting
Gut microbes can generate urolithin A from compounds in some foods. It is studied for mitophagy, the process of removing damaged mitochondria. Mitochondria help cells produce usable energy, so improving their quality is a plausible research goal.
The mechanism does not tell us whether people walk farther, avoid disability or live longer. Eating a source food, producing the metabolite and taking a defined supplement are also different exposures.
What does the evidence show?
Endurance signals alongside null primary outcomes
Sixty-six adults aged 65–90 received urolithin A or placebo for four months. Selected hand and leg endurance tests favoured treatment at two months, and several biomarkers changed. The primary six-minute walking and maximal ATP-production comparisons did not significantly improve. The trial was supported by Amazentis, which had a role in its conduct and analysis.
Read the research ↗Five small trials; walking benefit statistically inconclusive
Five randomised trials included 236 participants. Only two could be pooled for the six-minute walk test: the mean difference was about 17 metres, with a 95% confidence interval from 5 metres worse to 39 metres better. Certainty was low. Other strength, endurance and biomarker findings were heterogeneous exploratory signals, not reproducible pooled effects.
Read the research ↗Selected strength gains; the primary power test was negative
Singh and colleagues randomised 88 untrained, overweight middle-aged adults to 500 mg, 1,000 mg or placebo for four months. Selected leg-strength measurements improved, but the primary peak-power outcome did not. Lean body mass and hand-grip comparisons were not clearly improved. This is a useful functional signal, rather than only a biomarker finding, but it does not establish general rejuvenation. Amazentis sponsored the study and several authors were company employees or advisers. [5]
Read the research ↗An endurance signal is different from stronger lifts
Twenty resistance-trained men were studied for eight weeks. Compared with placebo, selected isometric strength and repetitions-to-failure tests improved, while bench-press and squat one-repetition maximum differences were not statistically significant. A small trial with several endpoints needs replication, and its outcomes should not be blended into a promise that every type of strength improves. [6]
Read the research ↗Does this show slower ageing?
No. A mitochondrial-related biomarker or fatigue-test improvement is not a demonstrated change in lifespan, disease-free survival or the overall rate of ageing. No such human outcome is established by these short trials.
A 2026 mechanistic review likewise describes human evidence as preliminary, concentrated in muscle or exercise measures, selected metabolic markers and short- to medium-term tolerability. Its animal and laboratory findings should not be converted into human longevity benefits. [3]
Can people feel the biomarker improvement?
That is the key unresolved translation. A blood marker is a clue about biology; a walking test measures function, and independence or quality of life measures everyday impact. Some trials report measured functional signals, but the pooled walking result remains inconclusive. The studies have not established that a changed mitochondrial marker causes a noticeable energy boost or protects against disability. [1,2,5,6]
The catch / limitations
The 2022 participants were predominantly women and all White, limiting generalisation. The research also involved selected older adults rather than a representative population of athletes or people with multiple illnesses. Commercial involvement makes independent confirmation valuable.
A statistically inconclusive result does not prove zero benefit. Its uncertainty range can allow modest benefit, but it does not justify certainty. Similarly, a positive secondary outcome deserves reporting alongside the primary outcomes rather than replacing them.
Safety and practical context
The four-month trial found no significant difference in adverse events and reported good tolerability in its studied population. That is reassuring within those limits, not proof of lifelong safety, safety in every condition or compatibility with every medicine.
The studied doses and formulations describe experiments. Ask about the actual product and your health context rather than assuming a higher dose accelerates mitochondrial renewal. Exercise and a supplement are different interventions; these studies do not establish a substitute for activity.
What this means for you
Ask whether a claimed result concerns an actual functional improvement or a biomarker. Both can be interesting, but they answer different questions.
An encouraging mechanism can justify further research without justifying a longevity promise or a guaranteed improvement in strength.
Early functional signals; no demonstrated slowing of human ageing.
Research & Sources
1. Liu et al.: Urolithin A and endurance, randomised trial (2022)
Original source ↗2. Urolithin A and muscle health, systematic review/meta-analysis (2026)
Original source ↗3. Urolithin A mechanisms and translational applications, review (2026)
Original source ↗4. Liu et al.: Full trial report and funding disclosures
Original source ↗5. Singh et al. (2022): middle-aged-adult ATLAS trial
Original source ↗6. Zhao et al. (2024): resistance-trained male athlete trial
Original source ↗Evidence reviewed: October 2026
Evidence vs Hype explains scientific research for educational purposes and does not provide individual medical diagnosis or treatment. Featured artwork illustrates the claim being investigated; conceptual insets do not demonstrate a proven biological effect.
Compare an experimental mitochondrial peptide: Does MOTS-c Really Burn Fat, Boost Energy and Slow Ageing?